- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Developmental stage.
Displaying page 1 of 2.
EudraCT Number: 2014-001411-39 | Sponsor Protocol Number: ABT-002 | Start Date*: 2018-09-04 |
Sponsor Name:Abeona Therapeutics Inc | ||
Full Title: Phase I/II gene transfer clinical trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB | ||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progre... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001559-38 | Sponsor Protocol Number: GEICAM/2018-06 | Start Date*: 2022-01-20 | ||||||||||||||||
Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | ||||||||||||||||||
Full Title: A Randomized Phase II Study to Evaluate the Incidence of Discontinuations due to Diarrhoea at 3 Cycles in patients with Early-stage HER2-positive (HER2+), Hormone Receptor-positive (HR+) Breast Can... | ||||||||||||||||||
Medical condition: HER2+, HR+ Early stage Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004860-78 | Sponsor Protocol Number: P1209NY | Start Date*: 2014-05-09 | |||||||||||
Sponsor Name:G. Pohl-Boskamp GmbH & Co. KG | |||||||||||||
Full Title: A randomised, active-controlled, observer-blind, non-inferiority study to investigate the efficacy, safety and tolerability of a local treatment with dimeticone-based pediculicides in head lice inf... | |||||||||||||
Medical condition: Pediculosis capitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001783-21 | Sponsor Protocol Number: 3288 | Start Date*: 2012-07-11 | |||||||||||
Sponsor Name:Childrens's Research Institute | |||||||||||||
Full Title: Optimizing Pain Treatment in Pre-Term Neonates | |||||||||||||
Medical condition: Critically Ill Premature Neonates between 23 and 32 weeks of gestation who are receiving morphine as part of their routine medical management of pain or other medically indicated condition for whic... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002425-21 | Sponsor Protocol Number: 11054 | Start Date*: 2012-02-10 |
Sponsor Name:University of Nottingham | ||
Full Title: Efficacy of Dehydroepiandrosterone to overcome the effect of ovarian aging | ||
Medical condition: Women having low ovarian reserve undergoing IVF/ICSI treatment | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001903-60 | Sponsor Protocol Number: EFC14643 | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents with Heterozygous Famil... | |||||||||||||
Medical condition: Hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) FR (Completed) IT (Completed) DE (Completed) AT (Completed) Outside EU/EEA NL (Completed) HU (Completed) SI (Completed) ES (Completed) PL (Completed) FI (Completed) BG (Completed) CZ (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002548-26 | Sponsor Protocol Number: 0139 | Start Date*: 2020-12-16 | ||||||||||||||||
Sponsor Name:Royal College of Surgeons in Irlenad | ||||||||||||||||||
Full Title: Can Pentoxifylline improve long-term outcomes in preterm infants with late-onset sepsis or necrotizing enterocolitis? A pragmatic, randomised, placebo controlled trial | ||||||||||||||||||
Medical condition: Late onset sepsis & necrotising enterocolitis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002379-40 | Sponsor Protocol Number: CAFQ056B2278 | Start Date*: 2012-01-09 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) Outside EU/EEA GB (Prematurely Ended) ES (Temporarily Halted) DK (Prematurely Ended) IT (Completed) FR (Completed) NL (Prematurely Ended) BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023777-19 | Sponsor Protocol Number: SToP-BPD | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants: the SToP-BPD study | |||||||||||||
Medical condition: bronchopulmonary dysplasia | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005336-23 | Sponsor Protocol Number: Baby-OSCAR | Start Date*: 2014-12-16 |
Sponsor Name:University of Oxford | ||
Full Title: Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies | ||
Medical condition: Patent ductus arteriosus of the newborn | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004184-79 | Sponsor Protocol Number: NIAD-01 | Start Date*: 2013-05-01 | |||||||||||
Sponsor Name:Dermal Laboratories Limited | |||||||||||||
Full Title: A placebo controlled evaluation of a developmental gel for the treatment of atopic eczema | |||||||||||||
Medical condition: The medical condition to be investigated in this study is atopic eczema, also known as atopic dermatitis. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002653-26 | Sponsor Protocol Number: PULMESCELL-2 | Start Date*: 2023-07-21 | |||||||||||
Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal | |||||||||||||
Full Title: PHASE II CLINICAL TRIAL TO ESTABLISH THE SAFETY OF THE USE OF EXPANDED ALLOGENEIC FETAL UMBILICAL CORD STEM MESENCHYMAL CELLS IN PRETERM PATIENTS WITH BRONCHOPULMONARY DYSPLASIA | |||||||||||||
Medical condition: Live newborns weighing ≤ 1250 grams and gestational age ≤ 28 weeks, who are on mechanical ventilation with a FiO2 ≥ 0.3 between days 5 and 14 of life, with no immediate extubation foreseeable | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2023-001104-33 | Sponsor Protocol Number: AT0071002 | Start Date*: 2023-12-22 | |||||||||||
Sponsor Name:Applied Therapeutics Inc. | |||||||||||||
Full Title: A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients with Classic Galactosemia (CG) | |||||||||||||
Medical condition: Galactosemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001785-17 | Sponsor Protocol Number: GENA-13 | Start Date*: 2011-09-27 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study in Previously Treated Children with Severe Haemophilia A to Investigate the Long-Term Immunogenicity, Tolerability and Efficacy of Human-cl rhFVIII | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) CZ (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001531-40 | Sponsor Protocol Number: WIL-30 | Start Date*: 2020-08-13 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Pediatric Patients with Severe Hemophilia A | |||||||||||||
Medical condition: Severe hemophilia A (<1% FVIII:C) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004058-11 | Sponsor Protocol Number: RM-493-023 | Start Date*: Information not available in EudraCT |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström syndrome (AS) Patients with Moderate to Severe Obesity | ||
Medical condition: Obesity and hyperphagia in patients with Bardet-Biedl Syndrome or Alström syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2007-006997-27 | Sponsor Protocol Number: CRAD001M2301 | Start Date*: 2011-06-01 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC) | ||
Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC). | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000618-20 | Sponsor Protocol Number: 40084-22084 | Start Date*: 2012-11-05 | |||||||||||
Sponsor Name:European Organization for the Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A PHASE II-R and A PHASE III TRIAL EVALUATING BOTH *ERLOTINIB (PH II-R) AND CHEMORADIATION (PH III) AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTED HEAD OF PANCREAS ADENOCARCINOMA | |||||||||||||
Medical condition: Patients with resected head of pancreas adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003739-32 | Sponsor Protocol Number: 1801 | Start Date*: 2020-02-28 | ||||||||||||||||
Sponsor Name:Actuate Therapeutics Inc | ||||||||||||||||||
Full Title: Actuate 1801: Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematological Malignan... | ||||||||||||||||||
Medical condition: Refractory Hematologic Malignancies or Solid Tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) PT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003441-38 | Sponsor Protocol Number: 1042-TSC-3001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Marinus Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) | |||||||||||||
Medical condition: Tuberous Sclerosis Complex (TSC)-related epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
